Abstract: The efficacy of treatment for intravenous elemental mercury intoxication has not been fully studied with regard to clinical outcome, and treatment recommendations vary. We treated a 41-year-old man with a history of drug abuse and depression who attempted suicide using 1 mL (13.53 g) metallic Hg i.v. He was admitted to the hospital 2 months later for dyspnoea and thoracic pain and was diagnosed with pneumonia. Hg deposits were seen in the lungs and extra-pulmonary organs. His blood level (372 lg/L) exceeded the population level of 5 lg/L by more than 70 times. Dimercaptopropane sulphonate sodium (DMPS; 600 mg/day orally) was administered for 14 days. One year later, the patient presented with dyspnoea on exertion, fatigue, depression and impaired sleep. His chest X-ray showed multiple opacities (size up to 2.8 cm), and psychological testing revealed a selective cognitive deficit in the area of visual attentiveness, flexibility, source memory and impairment of the motor speed of the dominant upper extremity. Mercury blood level was 158 lg/L and mercury urine output was 1380 lg/24 hr. DMPS (800 mg/day orally) was administered for 40 days; the patient eliminated up to 18 mg Hg/day. His Hg blood level and Hg urine output belong to the highest among reported cases. In spite of the therapy, the patient's blood Hg, complaints and psychological tests showed no improvement. This case report confirms that DMPS does not effectively remove intravenous deposits of metallic Hg.
Elemental mercury is well known for its severe toxicity, especially by inhalation [1] . Self-injections of metallic mercury have been mostly reported for suicidal attempts [2] but have also been documented for other purposes, such as attempts to improve physical strength [3] or sexual performance [4] .
Antidotal treatment using DMPS is most frequently used in Hg poisonings due to chronic inhalation, and Hg 2+ compounds [5] . Less is known about removing Hg after injections of metallic mercury, which are rare in the literature [6] [7] [8] [9] . There are uncertainties concerning the choice, indication and length of antidote treatment, especially if the symptoms are not completely specific. Therapy with the chelating antidote dimercaptopropane sulphonate sodium (DMPS) was used in our patient after i.v. Hg administration aiming to suppress his symptoms and to speed up Hg elimination.
Case Description
A 41-year-old man (176 cm, 104 kg body-weight), drug addicted for 25 years (using methamphetamine and opiates irregularly), with depressive episodes, attempted suicide using 1 mL (13.53 g) metallic Hg intravenously in January 2014, after he first used methamphetamine. Within an hour, he developed dyspnoea, blurred vision, motor disturbances and pain in the right thorax basis. He was admitted to the hospital 2 months later when his condition deteriorated due to bacterial pneumonia. Opacities consistent with mercury deposits were seen on his chest radiograph. In the lungs, there were many small ovoid deposits with a diameter up to 2.8 mm. Also computer tomography (CT) showed Hg opacities mainly in the lungs, most profusely in the subpleural region with additional small deposits in liver, kidneys, urinary tract and vertebral channel ( fig. 1 ). Metal deposits were found also in the right part of the heart, mainly in the right ventricle ( fig. 2) . No deposit was observed in the cubital region at the site of injection. Mercury blood concentration was 372 lg/L (reference level ˂5 lg/L), and urine concentration was 396 lg/L (reference level ˂2 lg/L or 10 lg/g creatinine). First treatment series with DMPS was given during the hospital stay for 14 days (600 mg/day orally), but the patient stopped using the medication immediately after the discharge. In July 2014 (6 months later), he quit abuse of all drugs. He was still smoking 30 cigarettes daily from the age of 20 years.
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Fifteen months after Hg injection, in March 2015, the patient presented with dyspnoea on exertion and psychological problems and was admitted to our department. Chest X-ray showed numerous metallic, rounded opacities localized mostly in the lower parts of the lungs, the largest up to 2.8 mm ( fig. 3) . Kidney function and blood pressure were in the normal range. Trittico 100 mg/day (trazodone) was administered for depression and sleeping problems and flavobion (silymarin) 210 mg/day for newly diagnosed chronic hepatitis type C.
Blood mercury level was 158 lg/L and mercury in urine reached 1620 lg/L, both measured by atomic spectroscopy (using AMA analyser, Altec, Czech Republic). Second series of chelation treatment with DMPS (800 mg/day) was started and continued for 20 days after 38 days' break and two short pauses -one-day gap due to suspected allergy and second 1.5 days' gap due to transient fever (38°C), which has been explained by bacteraemia due to dental root surgery the day before. The blood concentrations are shown in fig. 4 . The highest recorded daily urine output reached 18 mg Hg on day 2, as can be seen in fig. 5 .
Spirometry revealed a minor increase in total flow resistance (0.44 kPaxs/L, reference range <0.35 kPaxs/L), which did not explain the dyspnoea. Otherwise, the results were normal, including diffusion capacity for CO transfer factor in the lung for carbon monoxide corrected for haemoglobin (TLCOc).
Neurological examination revealed normal findings on the cranial and peripheral nerves, excepting diminished vibration sense (using a 128-Hz tuning fork) at the lower extremities that may suggest damage to the spinal posterior columns. Electromyography found normal motor and sensitive conduction velocities in the upper and lower extremities and normal findings in needle electromyography.
Magnetic resonance imaging (MRI) of the brain was performed on Gyroscan Phillips 1.5 T system with the following protocol: T1 weighted image (T1WI), T2WI and fluid-attenuated inversion recovery (FLAIR) with slice thickness 6.0/ 0.6 mm in transversal plates, T1WI and T2WI in coronal plates and T1WI after administration of gadolinium. Native scans and post-contrast scans did not reveal any focal or diffuse pathological findings in the brain parenchyma. Visually evoked potentials were evaluated using a twochannel device (TruTrace 4 Alien Technik, Czech Republic). The results were borderline, with relatively low and ill-defined N1 waves bilaterally and normal latency of the evoked complex.
The ophthalmological examination (visual acuity, colour vision, visual fields, contrast sensitivity and fundus examination) brought normal results, including optic nerve and retinal nerve fibre layer (OCT-RNFL) thickness imaging.
Screening for ethanol abuse did not give a positive result; both ethyl glucuronide and carbohydrate-deficient transferrin levels were within the reference range. Bilirubin and aspartate aminotransferase (AST) were in the normal range, gamma-glutamyltransferase (GGT) was already initially elevated and alanine aminotransferase (ALT) increased two times during DMPS treatment. On the other hand, proteinuria 0.29 g/24 hr (range 0.00-0.15) gradually normalized during the therapy.
Neuropsychological examinations before and after DMPS treatment showed a selective cognitive deficit in the area of visual attention, executive functions (set shifting) and impaired motor speed of the dominant upper extremity. The activities of daily living were preserved; global cognitive impairment was not present. No substantial improvement in cognitive performance after 2 months was observed, performance in some cognitive domains was even worse (frontal behaviour, delayed recall from memory), some slightly improved within the range of normal variability (visual attention, set shifting and motor speed), however, still below average according to normative standards for his education level and some remained on the same level (depressive symptoms, subjective memory complaints; table 1).
Despite increased Hg elimination during the antidote therapy, the dyspnoea, depression, sleeping problems and psychological findings of the patient did not show any improvement. DMPS treatment was stopped after totally 40 days (on 31 May 2015), when Hg urine output returned to the pre-treatment level (less than 1500 lg/L).
Discussion
Mercury i.v. injection belongs to rare metal intoxications, which bring severe diagnostic problems [10] [11] [12] [13] .
Patients intoxicated with mercury usually present with mood change to depression, shyness, combined with explosive irritability and frequent blushing ('erethism') [14] . Gingivitis, tremor and changes in peripheral nerve function and renal function (nephrotic syndrome) have also been reported, but they are less common than after chronic exposures by inhalation or chronic skin absorption of Hg 2+ containing creams [15, 16] .
After entering the body, mercury in the tissues is slowly oxidized to the mercuric ion (Hg 2+ ) by the enzyme catalase.
The divalent cation (Hg 2+ ) is capable of targeting sulphydryl (-SH) groups on structural proteins, receptors, enzymes, DNA and RNA rendering them inactive [16] . In the form of divalent inorganic Hg or as organic compounds, Hg may be eliminated by the kidneys; Hg excretion via the faeces is of minor importance [14, 15, 17] . Metallic mercury can be detected by imaging X-rays or CT as small globular metallic opacities. Ultrasound shows the mercury particles as small echogenic dots [18] . Metallic mercury particles may persist in the body for decades, especially in the lung vessels and/or in the heart [3] . Signal voids described on MRI that usually represent signal foreign bodies (such as wood or plastic) do not visualize Hg particles, as mercury is a diamagnetic metal. In our patient, MRI helped to exclude morphological damage in the brain and cerebellar tissue that could be related to his symptoms. In spite of a dramatic appearance on the X-ray, some patients survive several years or decades after intravenous mercury injection with mercury depots persisting in the lung with minor or no symptoms of mercury poisoning [19] . Obviously, Hg may deteriorate a patient's psychic disorder.
This patient differed from our other patient severely intoxicated from the Hg 2+ skin cream [16] who had polyneuropathy, nephrotic syndrome, hypertension and severe depression, but has shown some improvements in the neuropsychological parameters already after one-month DMPS therapy. On the other hand, no reliable improvement in cognitive performance after treatment was seen in the patient with intravenous Hg injection, who had a high level of depressive symptoms and subjective memory complaints, but preserved activities of daily living. There was a cognitive deficit in sustained visual attention, executive functions (set shifting) and upper limb motor speed both before and after chelation treatment in comparison with his average premorbid intelligence level. The latency to the beginning of DMPS treatment was rather long; therefore, the urine level could be higher due to long-term absorption, in comparison with other patients [2, 6, 20] . However, we cannot conclude that chelation therapy had a positive effect on the basic cognitive functions of this recently treated patient. The treatment recommendations for metallic i.v. injection vary; therapy should be considered in any patient who is symptomatic and/or who has a blood or urine mercury concentration that exceeds current reference ranges (more than 5 lg/ L in blood for recent/acute exposures and more than 10 lg/g creatinine in urine for chronic exposures [1, 21] ). The need for chelation in an asymptomatic patient has also been debated [22, 23] , but no definite conclusion was given [21] . Elemental mercury urine excretion half-life is 60-90 days, which, however, does not involve unabsorbed metallic droplets [24] .
There are also insufficient data to determine, which chelating agent is most efficient, but limited evidence favours DMPS [1] . In symptomatic acute or chronic Hg poisoning with metallic (elemental) mercury, oral DMPS enhanced urinary mercury excretion [25, 26] , although the effect on clinical outcome has not been fully studied [14] . Differently, the treatment of intoxication of our first patient with Hg2 + from the skin cream reversed the unfavourable course and increased Hg output by 1000x [16] . Similarly, DMPS has also been efficient in intoxications with cobalt where it improved the clinical condition of the patient [27] .
Dimercaptopropane sulphonate sodium itself does not dissolve the metallic deposits in organs which are supposed to free Hg continuously. There is also a lack of correlation between symptomatology and Hg levels in both blood and urine. In our patient, mercury blood concentrations remained fairly constant during the treatment period and follow-up, which has also been described in other patients [20, 28] . The efficacy of treatment in patients with metallic deposits is usually low. Some studies reported maximum 1-2 mg of Hg elimination/24 hr after DMPS or DMSA [20, 29] or 1.5-8 mg/L [20, 28] during the first days of the treatment and decreasing within the following days. A total of 10 days' chelation with DMPS and DMSA resulted in a total urinary mercury excretion of 11 mg, compared with an estimated injected dose of 20 g [20] . Urinary output in our patient following DMPS increased substantially (up to 18 mg/24 hr); still, the elimination of mercury seems negligible with respect to the injected dose of 13.5 g mercury.
Additionally, there is no clear guideline concerning the length of treatment, and a long-term therapy in a symptomatic patient has been recommended [30] . More commonly, fiveday courses have been suggested in parallel with monitoring the patient's blood and urine mercury concentrations during and after chelation therapy [1, 20] . The comparison of the first and second 20-day 800 mg/day courses showed that that the second one (with two short gaps) was less efficient (50% Hg elimination on day 20 in the comparison with day 20 of the previous 800 mg/day course) in our patient. The reason may be a very slow absorption of Hg from the deposits and therefore low efficiency of high and/or long-term doses, which do not promote intense elimination.
Adverse reactions to DMPS include skin reactions (rash, urticaria), mucous membrane ulcers and elevation in body temperature, mineral imbalance, triggering of kidney or liver failure, nausea, anorexia, diarrhoea, vomiting and neutropenia [1, 20] . Our patient experienced transient skin rash and a rise in liver enzyme activities during the therapy.
Conclusion
Intravenously injected elemental Hg can lead to an asymptomatic course of disease or give rise to neurological symptomatology, respiratory issues, kidney and liver failure, or even death [14, 31] . The blood level and urine output during the antidote treatment in our patient were the highest among reported cases [6, 28, 30, 32] . DMPS treatment did not effectively treat a patient given an intravenous injection of Hg. Notably, the patient had no deposits at the site of injection.
Although the pre-antidotal urine Hg concentration was 8009 higher than that observed in the general population and the antidote strongly increased Hg output, this treatment approach seems to have had no or limited clinical effect. In the absence of severe symptoms, clearly specific to Hg intoxication, chelating therapy does not seem justified. The clinical effect is rather low. There may be side effects, and the cost/ benefit ratio of the treatment is not sufficiently proven.
